中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 8
Aug.  2016
Turn off MathJax
Article Contents

Long-term therapeutic effect of transjugular intrahepatic portosystemic shunt in patients with intractable cirrhotic ascites and prognostic factors

DOI: 10.3969/j.issn.1001-5256.2016.08.019
  • Received Date: 2016-05-23
  • Published Date: 2016-08-20
  • Objective To investigate the long- term therapeutic effect of transjugular intrahepatic portosystemic shunt( TIPS) in patients with intractable cirrhotic ascites and prognostic factors. Methods A retrospective analysis was performed for the clinical data of 57 patients with intractable cirrhotic ascites who were received TIPS in our hospital from January 2009 to June 2014. Regular telephone follow- up was performed in all patients. Laboratory testing results and abdominal ultrasound and CT findings were examined. The improvement in ascites and survival were evaluated. The χ2test was applied for comparison of categorical data between groups. The Kaplan- Meier method was used to calculate the cumulative probability of survival and other cumulative probabilities,the log- rank test was used for survival difference analysis,the Cox regression model was used to analyze prognostic factors,and the receiver operating characteristic curve( ROC) and the area under the curve( AUC) were used to determine the optimal cut- off values of prognostic factors. Results The 1- year ascites remission rate after TIPS was93%,and the 1- and 2- year survival rates were 60% and 43%,respectively. The multivariate Cox regression analysis showed that Child-Pugh score( HR = 268,95% CI: 1. 009- 1. 594,P = 0. 042) and urea nitrogen( HR = 1. 143,95% CI: 1. 034- 1. 264,P = 0. 009,) were predictive factors for 1- year survival rate after TIPS in patients with intractable cirrhotic ascites. The area under the ROC curve of Child-Pugh score was 0. 699( P = 0. 011,95% CI: 0. 558- 0. 840),and the optimal cut- off value of Child- Pugh score was 8,with a sensitivity of75% and a specificity of 67%. The Kaplan- Meier survival analysis demonstrated that the 1- year survival rates of patients with Child- Pugh scores of ≤8 and > 8 were 82% and 38%,respectively( χ2= 10. 888,P = 0. 001). Conclusion TIPS is safe and effective in the treatment of intractable ascites,and Child- Pugh score ≤8 is a predictive factor for 1- year survival rate in such patients.

     

  • loading
  • [1] GINS P,CRDENAS A,ARROYO V,et al.Management of cirrhosis and ascites[J].N Engl J Med,2004,350(16):1646-1654.
    [2] GINS P,ANGELI P,LENZ K,et al.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.
    [3] RUNYON BA.Management of adult patients with ascites due to cirrhosis:update 2012[J].Hepatology,2013:1-25.
    [4]SANYAL AJ,GENNING C,REDDY KR,et al.The North American study for the treatment of refractory ascite[J].Gastroenterology,2003,124(3):634-641.
    [5]LEBREC D,GIUILY N,HADENGUE A,et al.Transjugular intrahepatic portosystemic shunt:comparison with paracentesis in patients with cirrhosis and refractory ascites:a randomized trial[J].J Hepatol,1996,25(12):135-144.
    [6] RSSLE M,OCHS A,GULBERG V,et al.A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites[J].N Engl J Med,2000,342(6):1701-1707.
    [7]GINS P,URIZ J,CALAHORRA B,et al.Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis[J].Gastroenterology,2002,123(6):1839-1847.
    [8] SALERNO F,MERLI M,RIGGIO O,et al.Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites[J].Hepatology,2004,40(8):629-635.
    [9] OCHS A,ROSSLE M,HAAG K,et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites[J].N Engl J Med,1995,332(5):1192-1197.
    [10] SAAB S,NIETO JM,LEWIS SK,et al.TIPS versus paracentesis for cirrhotic patients with refractory ascites[J].Cochrane Database Syst Rev,2006,4(4):CD004889.
    [11]WONG F,SNIDERMAN K,LIU P,et al.The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt[J].Gastroenterology,1997,112(3):899-907.
    [12]TAN HK,JAMES PD,WONG F,et al.Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion[J].J Gastroenterol Hepatol,2015,30(2):389-395.
    [13] CHUTAPUTTI A.Management of refractory ascites and hepatorenal syndrome[J].J Gastroenterol Hepatol,2002,17(4):456-461.
    [14]SENZOLO M,CHOLONGITAS E,TIBBALL J,et al.Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome[J].Eur J Gastroenterol Hepatol,2006,18(11):1143-1150.
    [15]BOYER TD.Transjugular intrahepatic portosystemic shunt:current status[J].Gastroenterology,2003,124(5):1700-1710.
    [16]ALBILLOS A,BANARES R,GONZALEZ M,et al.A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites[J].J Hepatol,2005,43(6):990-996.
    [17]SALERNO F,CAMMA C,ENEA M,et al.Transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis of individual patient data[J].Gastroenterology,2007,133(3):825-834.
    [18] NARAHARA Y,KANAZAWA H,FUKUDA T,et al.Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function:a prospective randomized trial[J].J Gastroenterol,2011,46(1):78-85.
    [19]BAI M,QI XS,YANG ZP,et al.TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites:an updated meta-analysis[J].World J Gastroenterol,2014,20(10):2704-2714.
    [20]FORREST EH,STANLEY AJ,REDHEAD DN,et al.Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis[J].Aliment Pharmacol Ther,1996,10(5):801-806.
    [21]DESCHNES M,DUFRESNE MP,BUI B,et al.Predictors of clinical response to transjugular intrahepatic portosystemic shunt(TIPS)in cirrhotic patients with refractory ascites[J].Am J Gastroenterol,1999,94(5):1361-1365.
    [22]BUREAU C,MTIVIER S,D'AMICO M,et al.Serum bilirubin and platelet count:a simple predictive model for survival in patients with refractory ascites treated by TIPS[J].J Hepatol,2011,54(5):901-907.
    [23]HA MEL B,GUILLAUDA O,ROMAN S,et al.Prognostic factors in patients with refractory ascites treated by transjugular intrahepatic porto-systemic shunt:from the liver to the kidney[J].Dig Liver Dis,2014,46(8):1001-1007.
    [24] PARVINIAN A,BUI JT,KNUTTINEN MG,et al.Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites[J].Diagn Interv Radiol,2014,20(1):58-64.
    [25]TAKI Y,KANAZAWA H,NARAHARA Y,et al.Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites[J].Hepatol Res,2014,44(8):871-877.
    [26]SERSTT,GUSTOT T,RAUTOU PE,et al.Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites[J].J Hepatol,2012,57(2):274-280.
    [27]HARROD-KIM P,SAAD WE,WALDMAN D,et al.Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites[J].J Vasc Interv Radiol,2006,17(10):1605-1610.
    [28]SANYAL AJ.Pros and cons of TIPS for refractory ascites[J].J Hepatol,2005,43(6):924-925.
    [29]WU X,DING W,CAO J,et al.Clinical outcome using the fluency stent graft for transjugular intrahepatic portosystemic shunt in patients with portal hypertension[J].Am Surg,2013,79(3):305-312.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2384) PDF downloads(488) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return